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Purpose: To study real-world ranibizumab therapy for treatment-naïve eyes with neovascular age-related
macular degeneration (nAMD) and to benchmark standards of care.
Design: Multicenter, national nAMD database study.
Participants: A total of 92 976 treatment episodes from 12 951 eyes of 11 135 patients.
Methods: Up to 5 years of routinely collected, anonymized data were extracted remotely from 14 United
Kingdom centers to a central database using an electronic medical record (EMR) system. Participating
centers used ranibizumab to treat nAMD using a loading phase of 3 monthly injections and a pro re nata
retreatment regimen. The minimum data set deﬁned before ﬁrst patient data entry and mandated by the EMR
system included age, Early Treatment Diabetic Retinopathy Study visual acuity (VA) at all visits, and injection
episodes.
Main Outcome Measures: Baseline VA, change in VA, number of treatments and clinic visits, and baseline
characteristics affecting VA change.
Results: Information from more than 300 000 clinic visits (2.8 million data points) were collated. Mean age at
ﬁrst treatment was 79.1 years, with a female preponderance of 1.7:1. Mean VA (letters) for eyes followed up for at
least 3 years from a baseline of 55 letters was 57 (þ2) letters at 1 year, 56 (þ1) letters at 2 years, and 53 (2)
letters at 3 years. The proportion of eyes that avoided moderate vision loss at years 1, 2, and 3 were 90%, 84%,
and 82%, respectively. The proportion of eyes with VA of 20/40 or better were: baseline, 16%; year 1, 30%; year
2, 30%; and year 3, 29%. The median number of treatments for eyes followed up for at least 3 years in years 1, 2
and 3 was 5, 4, and 4, respectively, and the median number of outpatient visits was 9.2, 8.2, and 8.2, respectively.
Baseline VA was related inversely to mean vision gain at 3 months. Older age was associated with lower pre-
senting VA.
Conclusions: Real-world visual outcomes achieved at a large number of centers across the United Kingdom
do not match the results achieved in most randomized trials, but they were delivered with substantially fewer
injections and hospital visits. This study provides important benchmark results that should be of interest to
patients, retina specialists, and commissioners of health care. This study demonstrates the EMR system’s po-
tential usefulness for future phase 4 and 5 clinical trials. Ophthalmology 2014;121:1092-1101 ª 2014 by the
American Academy of Ophthalmology.
*Supplemental material is available at www.aaojournal.org.
Open access under CC BY-NC-ND license.Intravitreal injection of ranibizumab is an established ther-
apy to treat neovascular age-related macular degeneration
(nAMD) and is the most commonly performed retinal pro-
cedure in the United Kingdom’s National Health Service
(NHS). Clinical practice was informed initially by the Anti-
Vascular Endothelial Growth Factor Antibody for the Treat-
ment of Predominantly Classic Choroidal Neovascularization
in Age-Related Macular Degeneration (ANCHOR) study
and the Minimally Classic/Occult Trial of the Anti-VEGF
Antibody Ranibizumab in the Treatment of Neovascular
Age-Related Macular Degeneration (MARINA) study, which
demonstrated that ranibizumab prevents central vision loss1092  2014 by the American Academy of Ophthalmology
Published by Elsevier Inc. Open access under CC BY-NC-ND license.and improves mean visual acuity (VA) at 2 years when
given at monthly intervals in eyes with subfoveal nAMD.1,2
In the United Kingdom, the National Institute of Health
and Clinical Excellence (NICE)3 approved the use of
ranibizumab in August 2008, leading to almost exclusive
usage of ranibizumab for nAMD in the NHS. In contrast to
the pivotal studies, in routine clinical practice in the United
Kingdom, ranibizumab therapy is administered almost
universally as a loading phase of 3 injections given at
monthly intervals followed by pro re nata (PRN) treatment
if active disease is detected at monthly assessment visits.
Under strict trial conditions, PRN therapy is slightly butISSN 0161-6420/14/$ - see front matter
http://dx.doi.org/10.1016/j.ophtha.2013.11.031
Writing Committee  nAMD Database Studystatistically signiﬁcantly worse than continuous monthly
therapy, as shown in the Comparison of AMD Treatments
Trials (CATT) and the Trial of Alternative Treatments
to Inhibit VEGF in Age-Related Choroidal Neovasculari-
sation.4e7 In most published case series from routine clinical
practice, the level of beneﬁt of PRN treatment seen in ran-
domized trials has not been achieved either using an attempted
monthly follow-up or a treat-and-extend strategy.8e13 Deliv-
ering the therapy with a recommendation of monthly assess-
ment and re-treatment for active disease makes substantial
demands on health care services and funding authorities.
Given the cost and intensity of the intervention, it is important
to understand what real-life outcomes are achieved and how
different departments compare in translating clinical trial re-
sults into clinical practice. Clinical trials are limited by a
restricted study population (entry criteria), for example,
excluding second treated eyes and having a limited number of
trial subjects, but results of such trials are widely assumed
to reﬂect future clinical practice. Improvement in VA,
although vital to prove the efﬁcacy of a drug, may not be the
best measure of the quality of clinical care where the ideal is to
detect and maintain patients with excellent vision. Although
phase 4 and 5 studies that occur after marketing authorization
(such as the Observe the Effectiveness and Safety of
Ranibizumab in Real Life Setting [Luminous] Trial;
available at: http://clinicaltrials.gov/show/NCT01318941;
accessed August 20, 2013) may help to produce additional
information on efﬁcacy and safety, their usefulness is
limited by selective recruitment and possible changes in the
behavior of treating physicians, so outcomes are likely to
diverge from real-life outcomes. Traditional audits involve
retrospective collection of incomplete data from small
numbers of patients in single centers and may not reﬂect
real-world results from entire populations of treated
patients.
In addition, there is a risk of publication bias with single-
center case series because they may be reluctant to report
low success rates.14 Robust real-world data are important to
enable individual surgeons or centers to benchmark their
own performance. The limitations of traditional audits and
phase 4 studies could be overcome in part if the data were
collected as a by-product of routine clinical care with a
predeﬁned structure to collect a core dataset, with compul-
sory data entry and missing data check, and from closer to
the total number of patients treated in the population.
Appropriately designed and used electronic medical re-
cord (EMR) systems offer the ability to capture and pool a
large proportion or even all of the treated patients’ data to
assess how clinical trial results translate into real-life
clinical outcomes. They have the beneﬁt that all data are
collected as a by-product of routine clinical practice, and
they can be designed to mandate capture of a deﬁned
minimum dataset. The United Kingdom has already
demonstrated how a specialty-speciﬁc EMR system can be
of beneﬁt in ophthalmology to deﬁne benchmark clinical
outcomes for cataract surgery and to individualize the risk
of posterior capsular rupture for patients.15e17 To date, the
United Kingdom has avoided the danger that EMR systems
can become simple data stores that do not help to improve
the quality of care.18 The aims of this study were to deﬁnebenchmark standards of care for treatment-naïve eyes
treated with ranibizumab for nAMD at a large number of
United Kingdom centers using a loading phase of 3
monthly injections followed by a PRN re-treatment
regimen.
Methods
Study Design
Two EMR systems from different companies in the United
Kingdom were known to collect nAMD treatment and assessment
data. Sites known to make comprehensive use of these systems
were contacted; however, only sites using 1 EMR system met the
deadline given with regard to permission to extract data. All data
therefore were derived from 1 supplier (Medisoft Ophthalmology,
Medisoft Limited, Leeds, UK). The lead clinician and Caldicott
guardian (who oversees data protection) at each center gave written
approval for the data extraction. Patient identiﬁers were stripped
out completely and site and clinician data were pseudoanonymized,
and on this basis, an ethics committee determined that formal ethics
approval was not required. This study was conducted in accordance
with the Declaration of Helsinki and the United Kingdom’s Data
Protection Act.
Settings
Fourteen NHS hospitals that deliver ranibizumab AMD treatment
services in England and Northern Ireland submitted data to this
study. Each site is the only NHS provider of nAMD care to their
local population, and very few patients switch between providers.
After NICE approval for the use of ranibizumab for nAMD in the
NHS in August 2008, all sites used this drug almost exclusively. In
1 center, patients who were deemed nonresponders were switched
to bevacizumab, but these numbers were extremely small (<1.0%
in 1 of 14 centers), and any eye documented as receiving bev-
acizumab at any time point was excluded from the analysis. Before
August 2008, some sites offered treatment with bevacizumab. Sites
that gave approval for data extraction in the predetermined time
frame were included. No sites declined to submit data, but a number
of sites failed to deliver data within the time frame requested.
Dates for Data Collection
The study was initiated on February 1, 2012, with Caldicott
guardian and lead clinician approval being achieved in 14 of the 18
centers contacted by March 2012, the date predetermined by the
study team as the cutoff before data extraction was to occur. Data
were delivered to the analysis team by the end of April 2012. All
approvals and data extraction were performed by April 2, 2012.
Follow-up
All patients had data extracted from the time of the ﬁrst injection of
ranibizumab up to April 2, 2012. A number of patients were lost to
follow-up, but it was not possible within the framework of this
study to determine the cause of loss to follow-up. To explore
whether incomplete follow-up had an impact on outcomes, change
in VA was plotted only for patients who completed a deﬁned
follow-up period and was compared with a similar plot for all
patients.
Variables
Analysis was restricted to treatment-naïve eyes undergoing rani-
bizumab therapy for nAMD. Eyes undergoing combined therapies1093
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excluded. The mode of data entry into the EMR system varied
slightly between sites. At all sites, collection of demographic data
(age, gender, and ethnicity) was dependent on automatic download
from the hospital’s patient administration system to the EMR
system, and therefore the completeness of these variables was not
under the control of the EMR system. When used optimally, pre-
injection, injection procedure, and follow-up assessment data were
entered live directly into the EMR system as an integral part of
routine clinical care by all members of staff. Several sites run
entirely paperless clinics and other sites have entirely electronic
data collection but print a copy to maintain the paper notes. The
EMR system used by centers in this study has a structured dataset
for the management of nAMD that allows pooling of the data ﬁelds
collected. Although this study itself is retrospective, the dataset
was deﬁned and set up before the date of ﬁrst data collection in this
study; that is, the mandated EMR data ﬁelds were deﬁned pro-
spectively and the EMR user could not exit a patient’s chart unless
these data were collected. This contrasts with a conventional
retrospective chart review with unstructured data and is more akin
to the electronic case report form used in clinical trials, but with the
data captured as a by-product of routine clinical care. Data
collected at all sites included VA for each eye (and the method of
measurement) and treatment, if required (with procedure details
and complications). The operative and postoperative local and
systemic complications ﬁelds were mandatory within the software
system, and a response had to be entered at each visit. In many
centers, the EMR system was used to collect a larger optical
coherence tomography dataset, including the presence or absence
of parameters that inﬂuence re-treatment decision making.Data Sources and Measurements
In this report, the best-measured VA before surgery was mostly the
best VA with refraction, habitual correction, pinhole, or a combi-
nation thereof, as measured on an Early Treatment Diabetic Reti-
nopathy Study chart letter score and then expressed as Early
Treatment Diabetic Retinopathy Study letters and logarithm of the
minimum angle of resolution (logMAR) vision in this study, but
some sites measured a refracted best-corrected VA at baseline.
Analysis for eyes with very low VA was undertaken by subs-
tituting counting ﬁngers, hand movements, and light perception
with 2.0, 2.3, and 2.7, respectively.19Efforts to Reduce Bias
Any center with an EMR system that the authors were aware of
via the EMR system providers were invited to submit data. An
arbitrary cutoff of 2 months was made, and only centers whose
data were extracted in this time were included. It is possible that
centers that use EMR systems and responded rapidly to the data
request are not reﬂective of the average treating center in the
United Kingdom.Number of Visits
Some centers run a 2-stop service (assessment and treatment on
different days). For ease of analysis and to allow a standardized
comparison of visit frequency between centers, additional visits
within a 2-week block were regarded as a single visit, with the
last recorded VA used for analysis purposes; hence, the data on
number of visits represents a normalized value to allow standard-
ized comparison between centers, rather than the precise number of
visits by the patient.1094Statistical Methods
Data were extracted using Medisoft Ophthalmology (Medisoft
Limited, Leeds, UK) for right and left eyes of patients who had had
at least 1 intravitreal injection of ranibizumab. Both STATA
software version 11 (StataCorp. 2009, Stata Statistical Software:
Release 11. College Station, TX) and SPSS software version 19
(IBM Corp. Released 2010. IBM SPSS Statistics for Windows,
Version 19.0. Armonk, NY) were used to combine, clean, reshape,
merge, recode, and analyze the data. To check for errors in
combining and reshaping large datasets, outcomes were veriﬁed
separately in both statistical software databases by the lead author
and statisticians (A.T., W.X., and C.B.). Regression analyses were
performed in STATA. The method used to calculate a conﬁdence
interval for a proportion was the Wilson score method without
continuity correction.20
Centers were chosen for this study on the basis that EMR
systems were used consistently to record all VAs and ranibizumab
injection procedures. In eyes for which data were not available for
a particular visit or that had been lost to follow-up, no missing
value substitutions were performed. The only exception to this rule
was baseline VA. Some treatment centers brought patients back for
an injection-only visit with no measurement of VA (n ¼ 1670)
after the initial treatment decision was made; hence the baseline
VA was taken from the prior assessment visit, so long as this was
within 2 weeks of the injection. This therefore was not missing data
per se, but rather reﬂects variation in treatment delivery. Analyses
were performed both including all patients initiated into the study
and comparing these with a cohort of patients who completed
follow-up to the ﬁnal time point. The nature of the EMR system
with a structured AMD assessment led to very low duplicate entries
(0.02% overall in the worst data ﬁeld).
Results
Participants
The 14 sites entered their ﬁrst treatment episodes into the EMR
systems during the following years: 2006 (2 sites), 2007 (5 sites),
2008 (4 sites), 2009 (1 site), and 2010 (2 sites). The ﬁrst recorded
ranibizumab injection was dated November 2006. Data were
extracted for 12 951 eyes of 11 135 patients receiving a total of
92 976 ranibizumab injections during 317 371 clinic visits at 14
United Kingdom hospitals. During follow-up, 21.60% (n ¼ 1816)
of these patients required treatment to both eyes (Fig 1).
Age, gender, and ethnicity data were imported from the general
hospital patient administration system and were not entered
manually into the EMR system. Age was recorded in 100% of
cases. The mean age at the time of the ﬁrst injection was 79.7 years
(Fig 2). Gender was recorded in all but 1 case (Table 1). The
female-to-male ratio was 1.7:1, but when adjusted using national
data from the 2011 census for ages 55 to 89 and assuming a similar
gender and age mix in the study population, the female-to-male
age-speciﬁc ratio decreased to 1.3:1. Data on ethnic origin were
as shown in Table 1. Ethnic origin data were limited because such
information often is not recorded in the hospital administration
system, but in the available data, there was a preponderance of
white patients (89.6% of recorded ethnicities).
Visual Acuity
Mean change in vision over time is shown in Figure 2. Data are
plotted for 3 groups of eyes: those completing at least 52 weeks
of follow-up, at least 104 weeks of follow-up, and at least 156
weeks of follow-up (nominally referred to as years 1, 2, and 3 in
this article).
Figure 1. Consolidated Standards of Reporting Trials-style diagram showing the patients and eyes treated in the study. EMR ¼ electronic medical record;
nAMD ¼ neovascular age-related macular degeneration; VEGF ¼ vascular endothelial growth factor.
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at least 3 years, the mean change from baseline (55 letters) was 58
(þ3) letters at peak gain time point, 57 (þ2) letters at 52 weeks, 56Figure 2. Bar graph showing the frequency of age at presentation for ﬁrst
eye treatment.(þ1) letters at week 104, 55 (þ0) letters at week 120, and 53 (2)
letters at week 156 (Fig 3). To explore whether different cohorts of
patients were associated with different proﬁles of mean change in
vision over time, plots looking at cohorts followed up for at least
52, 104, and 156 weeks were plotted (Fig 3). These demonstrated
a similar change in vision proﬁle over their overlapping periods
of follow-up.
The proportion of eyes that avoided moderate vision loss
(15 letters) were 90% at year 1, 84% at year 2, and 82% at year 3
(Fig 4). The proportion of eyes with VA of 20/40 or better was
16% at baseline, 30% at year 1, 30% at year 2, and 29% at year
3 (Fig 4A). A more complete understanding of the change inTable 1. Demographic Details
Variable
Male
(n [ 4071)
Female
(n [ 7062)
Not speciﬁed
(n [ 1)
Total
(n [ 11 135)
Age (yrs)
Mean 78.8 80.1 79 79.7
Median 80 81 79 81
IQR 74e84 76e86 e 75e85
Range 55e103 55e108 e 55e108
Ethnicity, no.
White 2208 3894 1 6103
Mixed 5 36 0 41
Asian 35 5 0 40
Black 9 20 0 29
Chinese 0 2 0 2
Other 0 5 0 5
Not recorded 212 379 0 591
Declined to state 1596 2728 0 4324
IQR ¼ interquartile range.
1095
Figure 3. Graph showing the mean visual acuity (VA; with standard error
bars) over time comparing patients with follow-up of at least 1, 2, or 3
years. ETDRS ¼ Early Treatment Diabetic Retinopathy Study; logMAR ¼
logarithm of the minimum angle of resolution; SE ¼ standard error.
Ophthalmology Volume 121, Number 5, May 2014vision in the population was obtained by box-and-whisker plots of
VA at different time points (Fig 5, available at www.
aaojournal.org) demonstrating median, mean, and dispersion of
the data (interquartile range and 5th and 95th percentiles). To see
if patients who did not complete follow-up were different from
those followed up for at least 168 weeks, data were plotted both for
(1) only eyes followed up for a complete 168 weeks (n ¼ 1138)
and (2) all eyes receiving at least 1 ranibizumab injection (n ¼
12 951 at time 0 and n ¼ 1138 at month 42; Fig 5, available at
www.aaojournal.org). Both boxplot proﬁles and change in mean
VA were similar for these 2 groups. A comparison of outcomes
and baseline demographics was made between eyes that had
their ﬁrst treatment 156 or more weeks before the date of data
collation and that completed at least 156 weeks of follow-up
versus those that did not. Eyes that completed follow up (n ¼
2241) compared with eyes that did not (n ¼ 2009) were younger by
almost 2 years (79.1 vs. 80.9 years), were more likely to be female
(54% vs. 46%), and had better mean vision at last follow-up (0.65
logMAR [standard deviation {SD}, 0.31 logMAR] vs. 0.73 log-
MAR [SD, 0.35 logMAR]).
Effect of Baseline Characteristics on Visual Acuity
Change
Visual acuity at 12 months was associated positively with baseline
acuity (coefﬁcient, 0.74; standard error [SE], 0.01; P< 0.001) and
associated negatively with age (coefﬁcient, 0.21; SE, 0.02;
P< 0.001; adjusted R2, 0.41). Change in VA at 12 months was
associated negatively with baseline VA (coefﬁcient, 0.28; SE,
0.01; P< 0.001) and age (coefﬁcient, 0.24; SE, 0.02; P< 0.001;
Fig 6).
Number of Visits
The mean number of outpatient visits (normalized to allow com-
parison of 1-stop and 2-stop services, as discussed in “Methods”)1096in years 1, 2, and 3 were 9.2, 8.2, and 8.2 for patients followed up
for up to, but not including, weeks 52, 104, and 156, respectively
(Table 2).
Number of Injections
Eyes followed up for at least 52 weeks (but not including week 52)
received a mean of 5.7 injections (median, 6; range, 1e13) in the
ﬁrst 52 weeks. Eyes followed up for at least 104 weeks received
a mean of 3.7 injections (median, 4; range, 0e13) in their second
year of therapy (weeks 52e104; Table 2). In the third year of
treatment, eyes received a mean of 3.7 injections (median, 4;
range, 0e12; Fig 7, available at www.aaojournal.org). The
median number of treatments given for all eyes followed up for
at least 3 years was 5 in year 1, 4 in year 2, and 4 in year 3.
Discussion
This study demonstrated that very large data sets of real-life
outcomes data on ranibizumab therapy can be collated
rapidly and efﬁciently. More than 92 000 treatment epi-
sodes, VA data from 300 000 outpatient visits, and more
than 2.8 million data items were obtained in 5 weeks from
initiation of the study. This wealth of data represents easily
the largest dataset obtained for evaluating treatment burden
and outcomes of ranibizumab therapy.8,10,12,13 The struc-
tured data entry system within the EMR system, deﬁned
before the data collection started, resulted in very few
duplicate entries (0.02% in the worst data ﬁeld). In the EMR
system used in this study, a mandated minimum dataset was
constructed that forced users to enter complete data at each
visit. This EMR system acted like an electronic case report
form in a clinical trial, that is, these data ﬁelds were pre-
deﬁned before any data collection started and were entered
prospectively, although in the study itself, data collection
was retrospective. Unlike an electronic case report form,
data were entered as part of routine clinical care and not as
an additional entry on top of clinical records. The only data
ﬁeld of limited reliability was ethnicity, which relied on
importing data from the hospital administration system into
the specialty-speciﬁc EMR system.
The study conﬁrmed that incidence of treated nAMD is
higher in women, with a 1.7:1 female-to-male ratio (similar
ratio to that of CATT), although when adjusted for the age-
and gender-speciﬁc data available from the England and
Wales 2011 census data (available at: http://www.ons.gov.
uk/ons/dcp171778_277794.pdf; accessed January 1, 2013),
the ratio falls to 1.3:1 for the age group 55 to 89 years
where detailed national data are available. This excess fe-
male incidence supports that suggested in a previous meta-
analysis.21
The MARINA and ANCHOR trials involved 24 in-
jections over 2 years and 12 injections over 1 year, respec-
tively. In contrast to these pivotal trials, the European product
label for ranibizumab and clinical practice in the United
Kingdom is to deliver 3 loading injections at monthly in-
tervals followed by PRN dosing. A drug and disease model
informed this practice, and a base-case analysis for the model
predicting 8.1 injections in the ﬁrst year and 6 injections in
the second year were used with the assumption that the same
clinical efﬁcacy as the pivotal trial would be achieved with
A B
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Figure 4. Bar graphs showing (A) the percentage of eyes with a Snellen equivalent of 20/40 or better and (B) the percentage of eyes with 20/200 or worse,
respectively, at 0, 1, 2, and 3 years. Bar graph showing (C) the percentage of eyes that gained 15 letters or more (moderate gain) from baseline visual acuity (VA)
at years 1 through 3 and (D) the percentage of eyes that lost fewer than 15 letters at the same time points. Error bars are 95% conﬁdence intervals.
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study suggest that the VA outcomes achieved in the pivotal
trials, ANCHOR and MARINA, are not translated into
clinical practice in the United Kingdom. This may be
explained by the much lower treatment frequency than ex-
pected either in the pivotal studies, in the CATT PRN arm,
or in the NICE drug and disease model estimate.3,22,23
Dichotomous VA outcomes (Fig 4) showed a lower
proportion of patients gaining 15 letters of vision compared
with baseline (17.4% at year 1 and 18% at year 2) than in
the ANCHOR, MARINA, and CATT continuous arms by
approximately 10% at week 52. Of note, the CATT PRN
arm had a 25% rate of 15-letter gainers at 1 year, which
increased to 30.7% at the 2-year time point. The difference
may be explained by either a lower frequency of follow-up,
fewer treatments, prolonged duration of symptoms, or in-
clusion of eyes with very good baseline VA. In the present
study, the mean change in VA outcomes are somewhere
between those found in the Phase IIIb, Multicenter, Ran-
domized, Double-Masked, Sham Injection-Controlled Study
of the Efﬁcacy and Safety of Ranibizumab in Subjects with
Subfoveal Choroidal Neovascularization [CNV] with or
without Classic CNV Secondary to Age-Related Macular
Degeneration (PIER study) (3 monthly loading injection then
quarterly injections ¼ 6 injections at ﬁxed dosing)24 andthose found in CATT (6.9 ranibizumab injections in the
PRN arm in year 1 and 5.7 ranibizumab injections in year 2).5
Other reasons for poor translation of clinical trial out-
comes into clinical practice may be differences in patient
population, which would affect the capacity for visual gain.
In particular, real-world cohorts include eyes with some
structural damage at the fovea, with subfoveal hemorrhage
or where blood is the largest lesion component, and with
very large lesions. Such patients usually are excluded from
clinical trials on the basis that they have very limited scope
for improvement. The mean age at presentation in this study
was slightly older than that in the CATT ranibizumab PRN
arm (79.7 vs. 78.4 years in CATT), and the mean baseline
VA was worse than that in CATT (0.62 logMAR [55 letters]
vs. 0.46 logMAR [61.5 letters]). Both the number of in-
jections and number of visits (median, 10; interquartile
range [IQR], 8e11) in the ﬁrst year and a median of 9 visits
(IQR, 7e10) in years 2 and 3 are fewer than expected in the
drug and disease model used by NICE or in the CATT PRN
arm. With regard to the proportion of eyes with VA of 20/40
or better, there was an increase from 16% at baseline to
approximately 30% at year 1 in this study that was main-
tained to year 3 and that is lower than that found in the
CATT PRN arm (39% of eyes 20/40 or better at baseline,
increasing to 63% at 1 year), but the proportionate increase1097
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Figure 6. Graphs showing subgroups of mean visual acuity (VA; with standard error bars) over time. A and B, Mean visual acuity change stratiﬁed by
baseline acuity for all eyes in 15-letter increments: (A) absolute acuity at each time point and (B) change from baseline. C and D, Mean visual acuity change
stratiﬁed by age in years for ﬁrst-treated eyes only in 10-year increments: (C) absolute acuity at each time point and (D) change from baseline. ETDRS ¼
Early Treatment Diabetic Retinopathy Study; logMAR ¼ logarithm of the minimum angle of resolution; SE ¼ standard error.
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relative to baseline was similar to that in CATT. This
therefore underlines the importance of taking into account
baseline status when trying to compare studies, although
differences also may be attributable to either problems of
delivery of therapy or difﬁculties for the patients in main-
taining regular follow-up, or both.
Effect of Missing Data
A number of methods have been proposed to deal with
missing data in controlled clinical trials, including using only
complete cases and replacing missing values with the last
observed value carried forward in longitudinal data or mean
values in nonlongitudinal data. None of these approaches is
satisfactory because they all have the potential to cause in-
efﬁciency of statistical estimators. Speciﬁcally, the last
observation carried forward replacement of missing data
would, in the case of mean VA declining (as in this study),1098bias the data toward a more positive outcome. In this article,
we are describing patients still being followed up 3 years after
starting treatment. Missing data would be a problem if we
make inferences about patient prognosis 3 years after the start
of treatment. Although imputation and techniques for dealing
with missing data are becoming common in clinical trials, this
is in part because of the need to preserve the randomization,
which is not an objective here. We clearly describe patients
who exit before 3 years, which enables readers to consider
how this may impact on ﬁndings. Patients may leave because
vision has improved and is stable or because their vision has
deteriorated and they no longer wish to, or are unable to,
attend clinics for injections. We do not know.
There was a high proportion of patients lost to follow-up,
and those eyes that were lost to follow-up had a slightly
worse VA at last visit. Eyes lost to follow-up were of
slightly older age, which is associated with both a higher
mortality rate and worse VA gain. Unlike clinical trials,
patients in real-world clinics have preexisting morbidities
Table 2. Number of Visits and Treatments by Year
Year 1 Year 2 Year 3
No. of ranibizumab
injections*
Mean
Median
Range
5.7
6
1e13
3.7
4
0e13
3.7
4
0e12
Visits per year*
Mean (SD)
Median (range)
IQR
9.2 (2.3)
10
8e11
8.2 (2.1)
9 (7–10)
8.2 (2.1)
9 (7e10)
IQR ¼ interquartile range; SD ¼ standard deviation.
*Only patients followed up for the entire year included.
Writing Committee  nAMD Database Studywhere the risk of death and noncompliance is high, and the
present trial had a loss to follow-up that was higher than that
reported in the main clinical trials.
Effect of Baseline Characteristics on Visual Acuity
Change
Baseline Visual Acuity. The very good baseline VA group
(VA, 0.3 to 0 logMAR) had a mean drop of 0.12 logMAR
(6-letter loss) by 52 weeks, and those with VA between
0 and 0.3 logMAR had a loss of 0.06 logMAR (3-letter
loss). In the few studies with data on outcomes of eyes
with baseline VA better than 70 letters (Snellen, 20/40),
such as that by Williams and Blyth25 and Ross et al,13 the
eyes with baseline vision better than 6/12 lost 0.5 letters
and 1.5 letters at 1 year, respectively. This has been
attributed to a ceiling effect in patients with very good
vision at baseline. Our study supports the outcomes found
in these previous studies in a much larger cohort of patients,
as well as demonstrating this effect in patients with very
good baseline VA (0.3 to 0 logMAR), that has not been
evaluated previously as a separate subgroup as well as
demonstrating a signiﬁcant relationship of both change in
VA and VA at 12 months to baseline VA. If outcomes of
therapy are just assessed by the metric of change in vision
from baseline, then this would suggest that patients with
good baseline vision are poor responders. In contrast, if we
look at maintaining a good VA state and view Figure 7A, it
shows that eyes in the very good baseline VA group
maintained a VA of 0.09 logMAR (81 letters) and 0.27
logMAR (72 letters) at the 104-week time point. The mean
VA lines for each of the VA subgroups separated at 0.3-
logMAR (15-letter) intervals do not cross up to the 24-
month point. This supports the use of ranibizumab at baseline
VA better than the entry criteria of either ANCHOR,
MARINA, or CATT. Although no single metric adequately
describes all the different changes that occur with ranibi-
zumab therapy over time, a useful metric for how ranibi-
zumab is delivered in a population may be the proportion of
patients with VA better than 20/40 at baseline and at sub-
sequent time points, because this represents a measure of
early access to treatment as well as effective delivery of the
therapy over time. Patients with this VA level also would be
able to meet the driving standard for the United Kingdom
and in American states such as California.Age. Unlike VA, age did not have such a major effect on
VA gain for most of the age subgroups studied. Age at
presentation of ﬁrst eye treatment with ranibizumab peaked
at 79 years for men and 80 years for women (Fig 2), and
the proportion seeking treatment rapidly tailed off at older
and younger ages. The youngest age groups gained more
vision initially than the older subgroups (Fig 6). The oldest
subgroup (95e105 years), although initially seeming to
gain similar levels of vision as the other groups, then lost
vision, and there was a lot of ﬂuctuation in acuity over
time. The oldest subgroup, however, had a relatively small
number (80 eyes at baseline and only 16 eyes followed up
for at least 2 years), which may explain the variability.
Looking at baseline acuity by age, there was a trend for
younger patients to have better baseline acuity of 0.56
logMAR (age, 55e65 years), 0.58 logMAR (age, 65e75
years), 0.65 logMAR (age, 75e85 years), 0.71 logMAR
(age, 85e95 years), and 0.75 logMAR (age, 95e105
years). Eyes from patients in the younger cohorts (and
better baseline vision) maintained a superior mean VA
relative to the next oldest subgroup during the study
follow-up, which supports the ﬁndings of the CATT study
that age has an inﬂuence on VA outcomes.26 It is possible
that the better baseline VA at presentation in the younger
age group is the result of earlier presentation, although the
possibility of either more aggressive presentation of CNV
or coexisting atrophy as a cause of lower presenting acuity
in older cohorts cannot be excluded. The greater gain in
VA in the younger groups is not explained by baseline VA
because better baseline VA in general is associated with
smaller VA gains.
What Is the Best Way to Plot Change in Visual
Acuity over Time?
Figure 6 highlights the difference in plotting change in acuity
relative to baseline versus actual logMAR or Early Treatment
Diabetic Retinopathy Study letter score over time. Most
studies plot mean change from baseline over time (CATT,
ANCHOR, MARINA, etc.). This is relevant in trials to
prove the efﬁcacy of a drug, but for patients, it is more
relevant to maintain better VA states over time because
substantial improvements in acuity may have relatively
little impact on activities of daily living if the ﬁnal VA
state is still poor. Plotting only mean change from baseline
over time focuses attention away from whether good levels
of VA are achieved and maintained. In contrast, plotting
mean acuity at each time point (Fig 6A and B) describes
the VA state of the study population and, given that
baseline VA affects vision gain, allows an understanding of
what VA gain potential there is in the study population.
Comparing box-and-whisker plots over time versus mean
VA highlights the spread of the data in the population
studied and shows the difference in median and mean. A
combination of presenting mean acuity change over time
together with a box-and-whisker plot (Fig 5, available at
www.aaojournal.org) gives a more complete understanding
of both the average and population change over time and
gives a much better representation of the total data points
available.1099
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Real-life delivery of therapy is problematic, with patients
having intercurrent illness limiting follow-up, becoming lost
to follow-up (death or moving to another area), or having
difﬁculty achieving regular follow-up because of trans-
portation or hospital capacity issues. To understand how
well we are delivering care, we need to understand the real-
life standard of care. United Kingdom clinical practice for
delivering ranibizumab therapy for nAMD almost exclu-
sively has been a loading phase of 3 monthly injections and
PRN re-treatment based on disease activity as judged by
optical coherence tomography scanning and fundal exami-
nation, although the compliance with the loading phase and
PRN re-treatment criteria was not assessed formally in this
study. The intended follow-up frequency has been monthly,
although because of capacity constraints, this is not ach-
ieved at all sites. Unlike the pivotal trials and CATT PRN
arm, there is less VA gain, vision tails off after the peak
gain, and there is a lower proportion of patients gaining 15
letters of vision or maintaining vision of 20/40 or better.
This represents what is currently being achieved in real life
and acts as a real-life outcomes benchmark with which to
compare local outcomes. These beneﬁts, however, are ob-
tained with fewer injections and fewer visits than the pivotal
studies or in the CATT trial. The results, with a subsequent
decrease in VA after maximum gain, are similar to those in
outcome studies with most of the published treat-and-extend
re-treatment approaches. Using change in VA alone is a
problematic benchmark because unless it is adjusted for case
mix, baseline VA and, to a lesser extent, age effect change
in VA. Outcome measures such as the proportion of treated
patients at baseline and 1, 2, and 3 years achieving speciﬁed
VA states and stability of vision after the maximum ach-
ieved together may be good metrics to use as standards. The
proportion of patients with VA of 20/40 or better will reﬂect
not just the efﬁcacy of the treatment but also how quickly
patients can access the treatment, and this cutoff reﬂects the
driving standard VA cutoff in many countries. The stability
of vision after the maximum gained reﬂects the ability
to follow up the patients and treat appropriately. Feedback
of these outcomes to the community and comparing local
outcomes with national averages may help treatment centers
to alter their delivery of care to try to improve outcomes.
The EMR systems such as the one used in this study provide
a detailed audit of clinical outcomes at the click of a button,
allowing each local site to compare their performance
against the national benchmarks deﬁned in this study.Potential Role in Future Phase 4 and 5 Studies
Increasingly, EMR systems are being adopted with the aim
that their implementation will improve quality, safety, and
efﬁciency of care,18 although published data to support their
positive impact is limited.27 Phase 4 trials involve safety
surveillance (pharmacovigilance) and ongoing technical
support of a drug after it receives permission to be sold.
The EMR system used in this study captures a structured
safety dataset for both local and systemic adverse events
that are compulsory data entry ﬁelds at each visit after1100the initial ranibizumab injection visit (not presented in
this article). Phase 5 is a growing term used in the
literature of translational research to refer to comparative
effectiveness research and community-based research; it
is used to signify the integration of a new clinical treatment
into widespread public health practice. The EMR study
described in this article demonstrated the power and speed
that very large datasets (>92 000 treatments episodes,
more than 2 800 000 data ﬁelds) of high quality can be
collated. The EMR used in this study already is being
used to populate automatically the prospective part of the
postapproval observational Luminous program (http://
clinicaltrials.gov/show/NCT01318941; accessed August
2013). These data are captured as part of routine clinical
care, thus avoiding the need for duplicate data entry into a
study database. In future, this could be done for all patients
receiving a new intervention because it comes to market
providing both phase 4 and 5 datasets in a more rapid and
complete way than currently at a much lower cost. In
addition, because the outcomes data obtained are a by-
product of normal clinical care, the outcomes obtained
from an EMR approach are more likely to reﬂect real-life
outcomes accurately than traditional phase 4 or 5 studies,
where there may be both selection bias and changes in the
behavior of patients and physicians who know that a study
is being undertaken.
This study provided pooled, anonymized data on the
demographics, visual outcome, treatment, and follow-up
burden of ranibizumab treatment for nAMD. Both baseline
VA and age inﬂuence VA outcome and change in VA. This
study supports the use of ranibizumab therapy at baseline
VA better than that used in the entry criteria of randomized
controlled clinical trials. The visual outcomes achieved in
this real-world cohort are worse than those achieved in the
randomized controlled clinical trials. It is likely that this is
because of a combination of capacity constraints
preventing intended monthly review at some centers,
reduced treatment frequency, and broader inclusion criteria
(i.e., a different case mix) in the real world compared with
clinical trials. Electronic medical record systems have the
potential to collate very large volumes of data rapidly.
This may enable retina specialist centers to benchmark
their outcomes and facilitate cost-beneﬁt analyses.References
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